%0 Journal Article
%A Jara-Palomares, Luis
%A Solier-Lopez, Aurora
%A Elias-Hernandez, Teresa
%A Asensio-Cruz, Maribel
%A Blasco-Esquivias, Isabel
%A Marin-Barrera, Lucia
%A de la Borbolla-Artacho, Maria Rodriguez
%A Praena-Fernandez, Juan Manuel
%A Montero-Romero, Emilio
%A Navarro-Herrero, Silvia
%A Serrano-Gotarredona, Maria Pilar
%A Sánchez-Díaz, José María
%A Palacios, Carlos
%A Otero, Remedios
%T Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
%D 2017
%U http://hdl.handle.net/10668/11419
%X The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1-6 and 7-12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p=0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p=0.02). The incidence of VTE recurrence at months 1-6 and 7-12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Treatment with tinzaparin beyond 6months is safe in patients with CAT.
%K Cancer
%K Low-molecular-weight heparin
%K Pulmonary embolism
%K Tinzaparin
%K Venous thromboembolism
%~